Greenphire CEO Sam Whitaker speaks on Sunshine Act and Clinical Trial Payments
KING OF PRUSSIA, Pa., Dec. 4, 2012 /PRNewswire-iReach/ -- Greenphire CEO Sam Whitaker spoke at the Sunshine Act and Aggregate Spend Bootcamp on the implications of the Physician Sunshine Act for the management of clinical trial payments and on advances in technology which streamlines financial reporting required to comply with the Act.
The discussion focused on how pharmaceutical, biotech, and medical device companies can use technology to gather and report on required data on clinical trial payments, which present a particular tracking challenge because each clinical trial may involve a complex series of payments made to multiple physician investigators across multiple clinical sites. To further complicate matters, payments may be made directly or by third parties like Contract Research Organizations (CROs). Sam's discussion also focused on best practices in preparing for the Act and on the ancillary benefits to sponsor organizations of implementing data aggregation technologies across clinical trials, which include increased automation, tracking, and accountability, and reduced costs and risk.
The presentation took place on Tuesday, December 4, 2012 in Philadelphia, PA. The Sunshine and Aggregate Spend Bootcamp is an intensive, hands-on seminar intended to prepare pharmaceutical and medical device companies for the requirements of complying with aggregate spend reporting under the Physician Sunshine Act.
Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced webâ€based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.